The serotonin transporter and emotionality: Risk, resilience, and new therapeutic opportunities

James W. Murrough; Dennis S. Charney

doi:10.1016/j.biopsych.2011.01.019

The serotonin transporter and emotionality: Risk, resilience, and new therapeutic opportunities

Research output: Contribution to journal › Comment/debate

17 Scopus citations

Original language	English
Pages (from-to)	510-512
Number of pages	3
Journal	Biological Psychiatry
Volume	69
Issue number	6
DOIs	https://doi.org/10.1016/j.biopsych.2011.01.019
State	Published - 15 Mar 2011

Access to Document

10.1016/j.biopsych.2011.01.019

Cite this

@article{0ed4354d393748cf99aee28067d78e71,

title = "The serotonin transporter and emotionality: Risk, resilience, and new therapeutic opportunities",

author = "Murrough, {James W.} and Charney, {Dennis S.}",

note = "Funding Information: Dr. Murrough receives research support from the National Alliance for Research on Schizophrenia and Depression and salary support from a research education grant from AstraZeneca to Mount Sinai School of Medicine. Dr. Charney has been named as an inventor on a use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression and received approval from the US Food and Drug Administration for this indication, Dr. Charney and the Mount Sinai School of Medicine could benefit financially.",

year = "2011",

month = mar,

day = "15",

doi = "10.1016/j.biopsych.2011.01.019",

language = "English",

volume = "69",

pages = "510--512",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "6",

}

TY - JOUR

T1 - The serotonin transporter and emotionality

T2 - Risk, resilience, and new therapeutic opportunities

AU - Murrough, James W.

AU - Charney, Dennis S.

N1 - Funding Information: Dr. Murrough receives research support from the National Alliance for Research on Schizophrenia and Depression and salary support from a research education grant from AstraZeneca to Mount Sinai School of Medicine. Dr. Charney has been named as an inventor on a use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression and received approval from the US Food and Drug Administration for this indication, Dr. Charney and the Mount Sinai School of Medicine could benefit financially.

PY - 2011/3/15

Y1 - 2011/3/15

UR - http://www.scopus.com/inward/record.url?scp=79952017976&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2011.01.019

DO - 10.1016/j.biopsych.2011.01.019

M3 - Comment/debate

C2 - 21353836

AN - SCOPUS:79952017976

SN - 0006-3223

VL - 69

SP - 510

EP - 512

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 6

ER -